'Temporary' reduction comes as companies bolster production capacity for the year
Additional option extends dosing from two weeks to four weeks
FDA priority review is based on data from the phase 3 FIDELIO-DKD trial
Chief scientific officer Paul Stoffels said J&J is aiming for one billion doses in 2021
Pfizer's rival 20-valent candidate was granted priority review in December 2020
CHMP could reach a decision on opinion by 29 January
EU approval is based on results from three phase 3 studies
Total number of doses secured by UK now totals 17 million
European Commission likely to formally approve the vaccine soon
Brexit means pharma must review its intellectual property rights across Europe
Continuity and stability are vital when it comes to the EMA's relocation when it leaves London
The committee also gives verdict on three other products
EU Commission approval comes on the same day as positive CHMP opinion
In June 2020, AZ signed a licensing deal with the Serum Institute for the vaccine
Swiss pharma is aiming for approval in first-line NSCLC
New administration offers same efficacy as subcutaneous injection
Time period between first and second vaccines has been extended in the UK
Vaccine found to be 79% effective in top-line results
Treatment can be administered as an injection instead of an intravenous infusion
Torbett initially joined the pharma association in March 2016
She joins the UK pharma body as its chief scientific officer
Chair of the board Michelle Brennan is among those newly elected
Will move to the global industry body from the Medicines Patent Pool
He joins the biopharma from Tang Capital Management
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...